Amneal Pharmaceuticals (AMRX) Net Cash Flow (2017 - 2026)

Amneal Pharmaceuticals' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$107.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 116.94% year-over-year to -$107.5 million; the TTM figure through Mar 2026 stood at $138.2 million (up 664.6% YoY), while the FY2025 annual figure was $196.2 million, up 865.93% from the prior year.
• Net Cash Flow was -$107.5 million for Q1 2026 at Amneal Pharmaceuticals, down from $74.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $155.4 million in Q3 2025 to a low of -$118.4 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$2.5 million across 5 years, with a median of -$1.9 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow slumped 885.96% in 2023, then soared 1137.19% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$56.9 million in 2022, then jumped by 105.8% to $3.3 million in 2023, then jumped by 1137.19% to $40.8 million in 2024, then surged by 83.12% to $74.7 million in 2025, then tumbled by 243.84% to -$107.5 million in 2026.
• The last three Net Cash Flow figures came in at -$107.5 million (Q1 2026), $74.7 million (Q4 2025), and $155.4 million (Q3 2025), per Business Quant data.